Home > Insider Trading > Biontech Se > Profile

Biontech Se (BNTX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Hedge Fund Popularity

Display

13F filing is ongoing

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on June 18, 2025, 3:30 pm based on SEC 13F filings Last update: June 18, 2025, 3:30 pm

No.	Hedge Fund	Shares	Value	Activity	% Port
1.	Viking Global Andreas Halvorsen	879,972	$80,130,250	-7%	0.25%
2.	Millennium Management Israel Englander	544,970	$49,624,968	+219%	0.03%
3.	Citadel Investment GroupCALL Ken Griffin	374,400	$34,092,864	-8%	0.01%
4.	Squarepoint Ops LLC Maxime Fortin (Cio)	347,727	$31,664,021	-6%	0.04%
5.	Tang Capital Management Kevin C. Tang	270,000	$24,586,200		1.36%

Institutional Investors' Holdings

Filing Period: Filing is Ongoing

No.	Name	Shares	Value	% Port
1.	Baader Bank Inc	151,862	$16,032,155	1.15%
2.	Swedbank Ab	39,900	$4,248,153	0%
3.	Crocodile Capital Partners Gmbh	29,586	$3,150,021	5.29%
4.	Tb Alternative Assets Ltd.	28,917	$3,078,793	0.57%
5.	Systrade Ag	10,000	$1,064,700	1.21%

News See All

Recent Agreements Set To Bolster BioNTech SE (BNTX)'s Oncology Arm

On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s investigational bispecific antibody...

Keep Reading →

July 9th, 2025 - News

13 Best German Stocks to Invest in Now

However, on a year-to-date basis, the DAX index has gained 19.48%, comfortably outperforming its US counterparts, driven by a robust show by the country’s defense stocks, as European governments unlocked...

Keep Reading →

July 8th, 2025 - Hedge Funds News

Truist Lifts BioNTech (BNTX) Price Target After New Partnership

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and co-commercialization of BioNTech SE’s (NASDAQ:BNTX) investigational bispecific antibody...

Keep Reading →

June 3rd, 2025 - News

Why BioNTech SE (BNTX) Skyrocketed On Monday

We recently published a list of These 10 Stocks Blew Past Expectations.

Keep Reading →

June 3rd, 2025 - News

Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market.

Keep Reading →

June 2nd, 2025 - News

Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal

On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation oncology therapies...

Keep Reading →

June 2nd, 2025 - News

BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion

German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing...

Keep Reading →

May 21st, 2025 - News